BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 11846063)

  • 1. Expression of Fas and Fas ligand in human gastric adenomas and intestinal-type carcinomas: correlation with proliferation and apoptosis.
    Osaki M; Kase S; Kodani I; Watanabe M; Adachi H; Ito H
    Gastric Cancer; 2001; 4(4):198-205. PubMed ID: 11846063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of Fas and Fas ligand system-associated apoptosis in gastric cancer.
    Ohno S; Tachibana M; Shibakita M; Dhar DK; Yoshimura H; Kinugasa S; Kubota H; Masunaga R; Nagasue N
    Ann Surg Oncol; 2000 Dec; 7(10):750-7. PubMed ID: 11129423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fas-related apoptosis in gastric adenocarcinoma.
    Lim SC
    Oncol Rep; 2003; 10(1):57-63. PubMed ID: 12469145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fas ligand upregulation is an early event in colonic carcinogenesis.
    Bennett MW; O'Connell J; Houston A; Kelly J; O'Sullivan GC; Collins JK; Shanahan F
    J Clin Pathol; 2001 Aug; 54(8):598-604. PubMed ID: 11477113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer.
    Bennett MW; O'connell J; O'sullivan GC; Roche D; Brady C; Kelly J; Collins JK; Shanahan F
    Gut; 1999 Feb; 44(2):156-62. PubMed ID: 9895372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of Fas ligand in gastric carcinoma relates to lymph node metastasis.
    Nagashima H; Mori M; Sadanaga N; Mashino K; Yoshikawa Y; Sugimachi K
    Int J Oncol; 2001 Jun; 18(6):1157-62. PubMed ID: 11351245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fas (Apo-1/CD95) and Fas ligand interaction between gastric cancer cells and immune cells.
    Lee TB; Min YD; Lim SC; Kim KJ; Jeon HJ; Choi SM; Choi CH
    J Gastroenterol Hepatol; 2002 Jan; 17(1):32-8. PubMed ID: 11895550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of Fas/FasL expression to cell apoptosis in Epstein-Barr virus-associated gastric carcinoma.
    He D; Xiao L; Chen JN; Liang Q; Shao CK
    Chin J Cancer; 2010 Mar; 29(3):283-7. PubMed ID: 20193111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fas receptor counterattack against tumor-infiltrating lymphocytes in vivo as a mechanism of immune escape in gastric carcinoma.
    Koyama S; Koike N; Adachi S
    J Cancer Res Clin Oncol; 2001 Jan; 127(1):20-6. PubMed ID: 11206267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of Fas ligand and sFas ligand in human gastric adenocarcinomas.
    Lim SC
    Oncol Rep; 2002; 9(1):103-7. PubMed ID: 11748465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fas ligand expression and its correlation with apoptosis and proliferation in Lobund-Wistar prostate carcinomas.
    Gutierrez LS; Noria F; Finol H; Sun L; Castellino F; Pollard M
    Pathobiology; 2005; 72(5):260-8. PubMed ID: 16374070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Action and mechanism of Fas and Fas ligand in immune escape of gallbladder carcinoma.
    Xu LN; Zou SQ; Wang JM
    World J Gastroenterol; 2005 Jun; 11(24):3719-23. PubMed ID: 15968727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma.
    Bennett MW; O'Connell J; O'Sullivan GC; Brady C; Roche D; Collins JK; Shanahan F
    J Immunol; 1998 Jun; 160(11):5669-75. PubMed ID: 9605174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of FAP-1 by human colon adenocarcinoma: implication for resistance against Fas-mediated apoptosis in cancer.
    Yao H; Song E; Chen J; Hamar P
    Br J Cancer; 2004 Nov; 91(9):1718-25. PubMed ID: 15494722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclooxygenase-2 expression in human gastric tubular adenomas and carcinomas; correlation with intratumoral microvessel density and apoptotic index.
    Honjo S; Kase S; Osaki M; Ardyanto TD; Kaibara N; Ito H
    Anticancer Res; 2004; 24(3a):1439-44. PubMed ID: 15274307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic significance of overexpression of the decoy receptor for Fas ligand (DcR3) in patients with gastric carcinomas.
    Takahama Y; Yamada Y; Emoto K; Fujimoto H; Takayama T; Ueno M; Uchida H; Hirao S; Mizuno T; Nakajima Y
    Gastric Cancer; 2002; 5(2):61-8. PubMed ID: 12111580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The evaluation of Fas/Fas ligand system in renal cell carcinoma--the effect of preoperative interferon-alpha therapy].
    Sejima T; Miyagawa I
    Nihon Hinyokika Gakkai Zasshi; 1999 Oct; 90(10):826-32. PubMed ID: 10565161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. c-FLIP expression in bladder urothelial carcinomas: its role in resistance to Fas-mediated apoptosis and clinicopathologic correlations.
    Korkolopoulou P; Goudopoulou A; Voutsinas G; Thomas-Tsagli E; Kapralos P; Patsouris E; Saetta AA
    Urology; 2004 Jun; 63(6):1198-204. PubMed ID: 15183989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fas ligand is up-regulated during the colorectal adenoma-carcinoma sequence.
    Belluco C; Esposito G; Bertorelle R; Alaggio R; Giacomelli L; Bianchi LC; Nitti D; Lise M
    Eur J Surg Oncol; 2002 Mar; 28(2):120-5. PubMed ID: 11884046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apoptosis and Fas-ligand expression correlate to the histopathological grade of gastric smooth muscle tumors.
    Liu Y; Chen C; Chen C; Hsieh H; Chang C; Shyu J; Yen C; Harn H
    J Surg Res; 2001 Feb; 95(2):92-8. PubMed ID: 11162031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.